A Bergamo Selected Research

Ruthenium

10/2015	Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
1/2015	Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.
1/2012	Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates.
1/2010	In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model.
1/2009	Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion.
4/2007	Ruthenium complexes can target determinants of tumour malignancy.
11/2003	Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
3/2002	Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A.
5/2001	Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
12/2000	Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A Bergamo Research Topics

Disease

11	Neoplasm Metastasis (Metastasis) 10/2015 - 04/2000
11	Neoplasms (Cancer) 10/2015 - 04/2000
6	Carcinoma (Carcinomatosis) 01/2010 - 04/2000
3	Adenocarcinoma 05/2001 - 09/2000
2	Breast Neoplasms (Breast Cancer) 01/2010 - 01/2009
2	Lewis Lung Carcinoma 12/2000 - 09/2000
1	Fish Diseases (Fish Disease) 12/2020
1	Fibrosis (Cirrhosis) 10/2015
1	Necrosis 03/2002

Drug/Important Bio-Agent (IBA)

13	RutheniumIBA 10/2015 - 04/2000
11	imidazolium- bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III) (NAMI-A)IBA 10/2015 - 04/2000
2	Matrix Metalloproteinases (MMPs)IBA 10/2015 - 01/2010
2	dichlorotetrakis(dimethyl sulfoxide)ruthenium II (trans-Ru)IBA 12/2000 - 09/2000
1	AlginatesIBA 12/2020
1	ChitosanIBA 12/2020
1	Coordination ComplexesIBA 01/2012
1	OsmiumIBA 01/2010
1	ethylenediamine (ethylenediamine dihydroiodide)FDA Link 01/2010
1	Lysine (L-Lysine)FDA Link 01/2010
1	Fibronectins (Fibronectin)IBA 01/2010
1	Human Serum Albumin FDA LinkGeneric 01/2010
1	diphenyl (biphenyl)IBA 01/2010
1	RM175IBA 01/2010
1	CollagenIBA 01/2010
1	IndazolesIBA 01/2009
1	indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))IBA 01/2009
1	MetalsIBA 04/2007
1	DNA (Deoxyribonucleic Acid)IBA 04/2007
1	Proteins (Proteins, Gene)FDA Link 11/2003
1	Transferrin (beta 2 Transferrin)IBA 11/2003
1	Serum AlbuminIBA 11/2003
1	AlbuminsIBA 11/2003
1	EnzymesIBA 03/2002
1	LigandsIBA 02/2002
1	Glutathione (Reduced Glutathione)IBA 02/2002
1	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 02/2002
1	Cysteine (L-Cysteine)FDA Link 02/2002
1	SolutionsIBA 02/2002
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 02/2002
1	SodiumIBA 12/2000
1	matrigelIBA 12/2000
1	PlasticsIBA 09/2000
1	Ruthenium CompoundsIBA 08/2000
1	Antineoplastic Agents (Antineoplastics)IBA 04/2000

Therapy/Procedure

1	Aftercare (After-Treatment) 01/2010
1	Drug Therapy (Chemotherapy) 04/2007
1	Radiotherapy 04/2007
1	Immunotherapy 09/2000
1	Therapeutics 08/2000